

NEWS EXPRESS

NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),

AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS

STN Operating Hours Plus Help Desk Availability

NEWS LOGIN

Welcome Banner and News Items

NEWS IPC8

For general information regarding STN implementation of IPC 8

NEWS X25

X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 19:10:40 ON 14 MAR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 19:10:46 ON 14 MAR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6 DICTIONARY FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

 $\label{thm:localing} \begin{tabular}{ll} $\tt Uploading C:\Documents and Settings\brobinson1\My Documents\strweb\Queries\43431.str \\ \end{tabular}$

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

Updated Search

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11 SAMPLE SEARCH INITIATED 19:16:11 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS 15 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 720 TO 1640 PROJECTED ANSWERS: 68 TO 532

L2 15 SEA SSS SAM L1

=> s 11 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 19:16:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1227 TO ITERATE

100.0% PROCESSED 1227 ITERATIONS 347 ANSWERS

SEARCH TIME: 00.00.01

L3 347 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
175.70
175.91

FILE 'HCAPLUS' ENTERED AT 19:16:20 ON 14 MAR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12 FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

Updated Search

substance identification.

=> s 13

7 L3 L4

=> s 14 and neville, a?/au

355 NEVILLE, A?/AU

L5 O L4 AND NEVILLE, A?/AU

=> s 14 and gomez, r?/au

1976 GOMEZ, R?/AU

1 L4 AND GOMEZ, R?/AU L6

=> d 16, ibib abs hitstr, 1

ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2005:158641 HCAPLUS

DOCUMENT NUMBER:

142:261546

TITLE:

Preparation of sulfonyl substituted

N-(biarylmethyl)aminocyclopropanecarboxamides as

bradykinin Bl antagonists or inverse agonists

Anthony, Neville J.; Gomez, Robert; Jolly,

Samson M.; Lim, John Jin; Su, Dai-shi

PATENT ASSIGNEE(S):

SOURCE:

Merck & Co., Inc., USA PCT Int. Appl., 57 pp. CODEN: PIXXD2

DOCUMENT TYPE:

INVENTOR(S):

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.					KIND		DATE		APPLICATION NO.					DATE			
W	WO 2005016886				A1		20050224		WO 2004-US25037					20040803			
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JΡ,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NΙ,
		NO,	ΝZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
	•	ТJ,	TM,	TN,	TR,	TT,	ΤZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:						MW,										
							RU,										
							GR,										
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,
		SN,	TD,	ΤG			•										
	AU 2004265300																
	CA 2534188							CA 2004-2534188									
E!	EP 1654232						EP 2004-779955										
	R:						ES,									MC,	PT,
							RO,										
	. CN 1832922				A 20060913				CN 2004-80022661					20040803			
JP 2007501790				T 20070201			JP 2006-522671 US 2006-565040					20040803					
				A1		2006	1102		US 2	006-	5650	40		_ 2	0060	118	
PRIORITY APPLN. INFO.:										003-							
											003-						
										WO 2	004-	US25	037		w 2	0040	803
OTHER SOURCE(S):				MAR	PAT	142:	2615	46									

GΙ

N-(Sulfonyloxybiarylmethyl)aminocyclopropanecarboxamide derivs. (I) [R1, AB R2 = H, C1-4 alkyl; R3a, R3b = H, (un)substituted C1-4 alkyl; R4a, R4b = H, halogen, (un) substituted C1-4 alkyl; or R4a and R4b together with the carbon atom to which they are both attached form an (un) substituted exocyclic methylene; R5 = each (un)substituted C1-6 alkyl, C3-8 cycloalkyl, C3-6 alkynyl, C2-6 alkenyl, (CH2)k-aryl, (CH2)k-heterocycle; R6a = -OSO2R8, -NR8aSO2R9, -C(R8b)(R8c)SO2R9; R6b, R6c, R6d = H, halogen, OSO2R8, (un) substituted C1-4 alkyl, cyano, nitro, ORa, CO2Ra, or when attached to adjacent carbon atoms R6C and R6d together with the carbon atoms to which they are attached form a 5- to 8-membered saturated or unsatd. ring; R7 = H, halogen, cyano, nitro, ORa, CO2Ra, C(O)NRbRc, (un) substituted C1-4 alkyl; R8 = H, each (un) substituted C1-4 alkyl, (CH2)k-aryl, or NH2; R8a, R8b, R8c = H, (un)substituted C1-4 alkyl; or when R6a and R6b are attached to adjacent atoms, R8a and R6b together complete 5- or 6-membered ring; R9 = each (un) substituted C1-4 alkyl, aryl, or (CH2)k-aryl; Ra, Rb, Rc = H, each C1-4 alkyl or Ph, C3-6 cycloalkyl; or NRbRc together forms a cyclic imide or a 4-, 5-, or 6-membered ring optionally containing an addnl. heteroatom selected from N, O, and S; X = CH, N; Y = C, S(0); k = 0, 1, 2]. These compds. are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin Bl pathway. Thus, N-[1-[[[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]amino]carbonyl]cyclopropyl]pyrimidine-5-carboxamide was coupled with 1-bromo-3-fluoro-2-methoxybenzene in the presence of tetrakis(triphenylphosphine)palladium(0) and potassium phosphate at 110° for 16 h to give N-[1-[[(3,3'-difluoro-2'-methoxy-1,1'biphenyl-4-yl)methyl]amino]carbonyl]cyclopropyl]pyrimidine-5-carboxamide which was treated with boron tribromide in CH2Cl2 at room temperature for 48 h to give N-[1-[[(3,3'-difluoro-2'-hydroxy-1,1'-biphenyl-4yl)methyl]amino]carbonyl]cyclopropyl]pyrimidine-5-carboxamide (II). II was stirred with tifluoromethanesulfonic anhydride in the presence of Et3N in CH2Cl2 at room temperature for 2 h to give

3,3'-difluoro-4'-[[[[1-[(pyrimidin-

5-ylcarbonyl)amino]cyclopropyl]carbonyl]amino]methyl]-1,1'-biphenyl-2-yltrifluoromethanesulfonate (III).

IT 845830-03-7P, N-[(lR)-1-(3,3'-Difluoro-2'-hydroxy-1,1'-biphenyl-4-yl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide 845830-07-1P, N-[(lR)-1-(5'-Chloro-3,3'-difluoro-2'-hydroxy-1,1'-biphenyl-4-yl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide

```
845830-25-3P, N-[(1R)-1-[2-Fluoro-4-(2-methoxy-1-
     naphthyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide
     845830-26-4P, N-[(1R)-1-[2-Fluoro-4-(2-hydroxy-1-
     naphthyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide
     845830-45-7P, N-[(1R)-1-(2'-Amino-3,3'-difluoro-1,1'-biphenyl-4-
     yl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide
     845830-51-5P, N-[(1R)-1-[2-Fluoro-4-(quinolin-8-yl)phenyl]ethyl]-1-
     [(trifluoroacetyl)amino]cyclopropanecarboxamide 845830-52-6P,
     N-[(1R)-1-[2-Fluoro-4-(1,2,3,4-tetrahydroquinolin-8-yl)phenyl]ethyl]-1-
     [(trifluoroacetyl)amino]cyclopropanecarboxamide
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; preparation of sulfonyl substituted N-
        (biarylmethyl)aminocyclopropanecarboxamides as bradykinin B1
        antagonists or inverse agonists for treatment or prevention of pain and
        inflammation)
     845830-03-7 HCAPLUS
RN
     Cyclopropanecarboxamide, N-[(1R)-1-(3,3'-difluoro-2'-hydroxy[1,1'-
CN
     biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

$$F_{3}C \xrightarrow[O]{H} O$$

$$Me$$

$$OH$$

$$F_{3}C$$

$$OH$$

$$OH$$

$$OH$$

RN 845830-07-1 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-(5'-chloro-3,3'-difluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CAINDEX NAME)

RN 845830-25-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-(2-methoxy-1-naphthalenyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-26-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-(2-hydroxy-1-naphthalenyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-45-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-(2'-amino-3,3'-difluoro[1,1'-biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 845830-51-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-(8-quinolinyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-52-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-(1,2,3,4-tetrahydro-8-quinolinyl)phenyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

```
845830-02-6P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
IT
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
    vl trifluoromethanesulfonate 845830-04-8P, 3,3'-Difluoro-4'-
     [(1R)-1-[[[1-[[(trifluoromethyl)sulfonyl]amino]cyclopropyl]carbonyl]amino]
    ethyl]-1,1'-biphenyl-2-yl trifluoromethanesulfonate 845830-05-9P
      3,3'-Difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbon
    yl]amino]ethyl]-1,1'-biphenyl-2-yl methanesulfonate 845830-06-0P
     , 5-Chloro-3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cycloprop
    yl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-yl trifluoromethanesulfonate
     845830-09-3P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
     yl ethanesulfonate 845830-11-7P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
     yl propane-1-sulfonate 845830-12-8P, 3,3'-Difluoro-4'-[(1R)-1-
     [[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-
     biphenyl-2-yl propane-2-sulfonate 845830-13-9P,
     3,3'-Difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl
     [amino]ethyl]-1,1'-biphenyl-2-yl benzenesulfonate 845830-14-0P,
     3,3'-Difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl
     ]amino]ethyl]-1,1'-biphenyl-2-yl phenylmethanesulfonate
     845830-15-1P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
     yl dimethylsulfamate 845830-16-2P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
     yl 2,2,2-trifluoroethanesulfonate 845830-17-3P,
     3,3'-Difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl
     ]amino]ethyl]biphenyl-2-yl 4-acetylbenzenesulfonate 845830-18-4P
     , 3-Chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]c
     arbonyl]amino]ethyl]-1,1'-biphenyl-2-yl trifluoromethanesulfonate
     845830-23-1P, 3'-Fluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-2-
     [[(trifluoromethyl)sulfonyl]oxy]-1,1'-biphenyl-3-yl
     trifluoromethanesulfonate 845830-24-2P, 1-[3-Fluoro-4-[(1R)-1-
     [[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]phenyl]napht
     halen-2-yl trifluoromethanesulfonate 845830-33-3P,
     N-[(1R)-1-[2'-[[4-(Acetylamino)phenyl]sulfonyl]amino]-3,3'-
     difluorobiphenyl-4-yl]ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxa
     mide 845830-39-9P, N-[(1R)-1-[3,3'-Difluoro-2'-
     [[(trifluoromethyl)sulfonyl]methyl]-1,1'-biphenyl-4-yl]ethyl]-1-
     [(trifluoroacetyl)amino]cyclopropanecarboxamide 845830-44-6P,
     N-[(1R)-1-[3,3'-Difluoro-2'-[[(trifluoromethyl)sulfonyl]amino]-1,1'-
     biphenyl-4-yl]ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide
     845830-50-4P, N-[(1R)-1-[2-Fluoro-4-[1-[(trifluoromethyl)sulfonyl]-
     1,2,3,4-tetrahydroquinolin-8-yl]phenyl]ethyl]-1-
     [(trifluoroacetyl)amino]cyclopropanecarboxamide
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation\ of\ sulfonyl\ substituted\ N-(biarylmethyl)\ aminocyclopropanecarbox
        amides as bradykinin B1 antagonists or inverse agonists for treatment
        or prevention of pain and inflammation)
RN
     845830-02-6 HCAPLUS
CN
     Methanesulfonic acid, trifluoro-, 3,3'-difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-
     yl ester (9CI) (CA INDEX NAME)
```

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} O O O$$

RN 845830-04-8 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoromethyl)sulfonyl]amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3C}$$
 NH
 O
 Me
 O
 O
 O
 O

Absolute stereochemistry.

RN 845830-06-0 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 5-chloro-3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-

yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-09-3 HCAPLUS

CN Ethanesulfonic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow NH \longrightarrow Me \longrightarrow O \longrightarrow O$$

RN 845830-11-7 HCAPLUS

CN 1-Propanesulfonic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

$$F_{3}C \longrightarrow NH \longrightarrow Me \longrightarrow O \longrightarrow O$$

Absolute stereochemistry.

$$F_{3}C \longrightarrow NH \longrightarrow Me \longrightarrow O \longrightarrow O$$

RN 845830-13-9 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'[(phenylsulfonyl)oxy][1,1'-biphenyl]-4-yl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$0$$

$$Me$$

$$0$$

$$0$$

$$0$$

RN 845830-14-0 HCAPLUS
CN Benzenemethanesulfonic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-

yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} \overset{H}{\underset{O}{\overset{N}{\underset{Me}{\bigvee}}}} \overset{F}{\underset{N}{\underset{Me}{\bigvee}}} \overset{F}{\underset{O}{\underset{O}{\bigvee}}} \overset{F}{\underset{O}{\underset{O}{\bigvee}}} \overset{F}{\underset{O}{\underset{O}{\bigvee}}} \overset{F}{\underset{O}{\underset{O}{\bigvee}}} \overset{F}{\underset{O}{\underset{O}{\longleftarrow}}} \overset{F}{\underset{O}{\longleftarrow}} \overset{F}{\underset{$$

RN 845830-15-1 HCAPLUS

CN Sulfamic acid, dimethyl-, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-16-2 HCAPLUS

CN Ethanesulfonic acid, 2,2,2-trifluoro-, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

$$F_{3}C \longrightarrow NH \longrightarrow Me$$

$$O \longrightarrow O$$

$$O \longrightarrow CF_{3}$$

RN 845830-17-3 HCAPLUS

CN Benzenesulfonic acid, 4-acetyl-, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 O
 Ac

RN 845830-18-4 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-23-1 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2,3-diyl ester (9CI) (CA INDEX NAME)

RN 845830-24-2 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 1-[3-fluoro-4-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]phenyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-33-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2'-[[[4-(acetylamino)phenyl]sulfonyl]a mino]-3,3'-difluoro[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 845830-39-9 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'[[(trifluoromethyl)sulfonyl]methyl][1,1'-biphenyl]-4-yl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow NH \longrightarrow Me \longrightarrow O \longrightarrow O$$

RN 845830-44-6 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'[[(trifluoromethyl)sulfonyl]amino][1,1'-biphenyl]-4-yl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 845830-50-4 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-[1,2,3,4-tetrahydro-1[(trifluoromethyl)sulfonyl]-8-quinolinyl]phenyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 19:10:40 ON 14 MAR 2007)

1

FILE 'REGISTRY' ENTERED AT 19:10:46 ON 14 MAR 2007

L1 STRUCTURE UPLOADED

L2 15 S L1

L3 347 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 19:16:20 ON 14 MAR 2007

L4 7 S L3

L5 0 S L4 AND NEVILLE, A?/AU

L6 1 S L4 AND GOMEZ, R?/AU

=> s 14 not 16

L7 6 L4 NOT L6

=> s 17 and jolly, s?/au

277 JOLLY, S?/AU

L8 0 L7 AND JOLLY, S?/AU

=> s 17 and lim, j?/au

4025 LIM, J?/AU

L9 0 L7 AND LIM, J?/AU

=> s 17 and su, d?/au

1801 SU, D?/AU

L10 2 L7 AND SU, D?/AU

 \Rightarrow d 110, ibib abs hitstr, 1-2

L10 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:633647 HCAPLUS

DOCUMENT NUMBER:

139:179895

TITLE:

Preparation of N-biphenylmethyl

cycloalkanecarboxamides as bradykinin antagonists for treatment of conditions associated with the bradykinin

B1 pathway.

INVENTOR(S):

Wood, Michael R.; Anthony, Neville J.; Bock, Mark G.;

Feng, Dong-Mei; Kuduk, Scott D.; Su, Dai-Shi

; Wai, Jenny Miu-Chun

PATENT ASSIGNEE(S):

Merck & Co., Inc., USA PCT Int. Appl., 89 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATI	E 	APPLICAT	TION NO.	DATE			
WO 2003066577		30814				20030204		
W: AE, AG, AL,	AM, AT, AU	, AZ, B	A, BB, BG,	BR, BY,	BZ, CA	CH, CN,		
CO, CR, CU,								
GM, HR, HU,								
LT, LU, LV,	MA, MD, MG	, MK, MI	N, MW, MX,	MZ, NO,	NZ, OM	1, PH, PL,		
PT, RO, RU,				TM, TN,	TR, TI	, TZ, UA,		
UG, US, UZ,				IIC 7M	7 ta 7 N	1 7 DV		
RW: GH, GM, KE, KG, KZ, MD,								
	GR, HU, IE							
BJ, CF, CG,								
US 2003220375		31127	US 2003-		011, 12	20030130		
US 6919343		50719	00 2000					
CA 2474373		30814	CA 2003-	-2474373		20030204		
AU 2003216169		30902	AU 2003-			20030204		
BR 2003007508	A 200	41207	BR 2003-	-7508		20030204		
EP 1501787	A1 200	50202	EP 2003-	-737624		20030204		
EP 1501787		51109				-		
R: AT, BE, CH,	DE, DK, ES							
IE, SI, LT,	LV, FI, RO				EE, HU			
US 2005084463		50421	US 2003-			20030204		
JP 2005517006		50609	JP 2003-			20030204		
CN 1630633 AT 309202		50622 51115	CN 2003- AT 2003-			20030204 20030204		
ES 2250899		60416		-737624		20030204		
NZ 534062		60630	NZ 2003-			20030204		
IN 2004CN01753		60224	IN 2004-			20040805		
NO 2004003739		41029	NO 2004-			20040907		
PRIORITY APPLN. INFO.:				-355062P	P	20020208		
				-410172P	P	20020912		
\			WO 2003-	-US3338	W	20030204		
OTHER SOURCE(S):	MARPAT 139	:179895						
GI	\	•						
\	\							
\			14 /	000				
1		2446	11/	()))				
1	//))(
\	10		14 /					
\				M				
Updated Search 🔪	ľ) Y				
\		() /	// 06	•				
	101505	10/	-					

Title compds. [I; R1, R2 = H, alkyl; R3 = H, alkyl, haloalkyl; R31 = AΒ alkyl, haloalkyl; R4, R41 = H, halo, (substituted) alkyl; R4R41 = atoms to form (substituted) methylene; R5 = alkynyl, (substituted) alkyl, alkenyl, cycloalkyl, ar(alkyl), heterocyclyl(alkyl), etc.; R6 = cycloalkyl, halo, cyano, NO2, (substituted) alkyl, alkenyl, amino, acylamino, heterocyclyl, acyl, etc.; R61, R62 = H, R6; R7, R71 = H, halo, cyano, NO2, alkyl, haloalkyl, amino, CO2H, etc.; m = 0, 1], were prepared for treatment of pain and inflammation (no data). Thus, tert-Bu (1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethylcarbamate (preparation given), Me 2-fluoro-6-iodobenzoate, K2CO3, tri-o-tolylphosphine, and palladium acetate were heated at 90° for 18 h in THF/H2O to provide Me 4'-[(1R)-1-[(tert-butoxycarbonyl)amino]ethyl]-3-fluoro-1,1'biphenylcarboxylate. This was treated with HCl in MeOH to give an amine hydrochloride. The above amine hydrochloride along with 1-[(tert-butoxycarbonyl)amino]cyclopropanecarboxylic acid, HOBt.H2O, triethylamine, and EDCI were stirred 16.5 h in THF to give 86% Me 4'-[(1R)-1-[[[1-[(tert-butoxycarbonyl)amino]cyclopropyl]carbonyl]amino]eth yl]-3-fluoro-1,1'-bibiphenyl-2-carboxylate. This was stirred with HCl in MeOH to give a solid amine hydrochloride. The above amine hydrochloride, trifluoropropionic acid, HOBt.H2O, triethylamine, and EDCI in THF/DMF were stirred 18 h to give 67% Me 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3trifluoropropanoyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-bibiphenyl-2-carboxylate. 578727-64-7P 578727-65-8P 578727-66-9P IT 578727-67-0P 578727-68-1P 578727-69-2P 578727-70-5P 578727-71-6P 578727-72-7P 578727-73-8P 578727-75-0P 578727-77-2P 578727-78-3P 578727-81-8P 578727-85-2P 578727-87-4P 578727-90-9P 578727-92-1P 578727-94-3P 578727-95-4P 578727-96-5P 578727-97-6P 578727-98-7P 578727-99-8P 578728-00-4P 578728-02-6P 578728-03-7P 578728-04-8P 578728-05-9P 578728-07-1P 578728-09-3P 578728-10-6P 578728-11-7P 578728-12-8P 578728-13-9P 578728-14-0P 578728-16-2P 578728-18-4P 578728-19-5P 578728-20-8P 578728-21-9P 578728-22-0P 578728-23-1P 578728-24-2P 578728-25-3P 578728-27-5P 578728-29-7P 578728-30-0P

578728-32-2P 578728-35-5P 578728-36-6P

```
578728-37-7P 578728-39-9P 578728-40-2P
     578728-41-3P 578728-44-6P 578728-46-8P
     578728-48-0P 578728-51-5P 578728-53-7P
     578728-55-9P 578728-56-0P 578728-57-1P
     578728-58-2P 578728-59-3P 578728-60-6P
     578728-61-7P 578728-62-8P 578728-63-9P
     578728-64-0P 578728-65-1P 578728-66-2P
     578728-68-4P 578728-70-8P 578728-71-9P
     578728-72-0P 578728-73-1P 578728-75-3P
     578728-76-4P 578728-77-5P 578728-78-6P
     578728-79-7P 578728-84-4P 578728-86-6P
     578728-87-7P 578728-88-8P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (claimed compound; preparation of biphenylmethyl cycloalkanecarboxamides as
        bradykinin antagonists for treatment of conditions associated with
        bradykinin Bl pathway)
     578727-64-7 HCAPLUS
RN
     [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-
CN
     trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl
     ester (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

RN 578727-65-8 HCAPLUS

[1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N-methoxy-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

RN 578727-66-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[1-methyl-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578727-67-0 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-68-1 HCAPLUS
[1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578727-69-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-70-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(cyanoacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-72-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-73-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578727-77-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1S)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-78-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 O
 O
 Me

RN 578727-81-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-85-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1S)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-87-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-(acetylamino)cyclopropyl]carbonyl]amino]ethyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-90-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-94-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-4'-[(1R)-1-[[[1[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

RN 578727-96-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl
]-, methyl ester (9CI) (CA INDEX NAME)

RN 578727-97-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-4'-[(1R)-1-[[[1[(difluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-98-7 HCAPLUS
CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[3'-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578727-99-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[3'-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-00-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-02-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 578728-03-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-04-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-05-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-07-1 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-09-3 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(difluoroacetyl)amino]-N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-(9CI) (CA INDEX NAME)

RN 578728-10-6 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[3'-fluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-11-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(lR)-1-[3'-fluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-12-8 HCAPLUS
CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[3'-fluoro-2'-(1-methyl-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-13-9 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(1-methyl-1H-tetrazol-5-y1)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-14-0 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[3'-fluoro-2'-(1-methyl-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-16-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

$$F_{3}C-CH_{2}-C-NH$$

$$O$$

$$Me$$

$$C-NH-CH$$

$$Me$$

$$N=N$$

RN 578728-18-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-19-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-20-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(difluoroacetyl)amino]-N-[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-21-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-(2'-cyano-3'-fluoro[1,1'-biphenyl]-4-yl)ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$CN$$

$$F_{3}C$$

RN 578728-22-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2'-(difluoromethoxy)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-23-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-4-

Updated Search

yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)
Absolute stereochemistry.

$$F_3C$$

NH

NH

NH

NH

NH

CF3

RN 578728-24-2 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

NH

O

NH

O

NH

O

Me

RN 578728-25-3 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-(2',3'-dichloro[1,1'-biphenyl]-4yl)ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

$$F_3C$$
 NH
 O
 Me
 $C1$

RN 578728-27-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[3'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-29-7 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-(2',3'-dichloro[1,1'-biphenyl]-4-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

RN 578728-30-0 HCAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(1R)-1-[[[1-[(cyanoacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 578728-32-2 HCAPLUS
[1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N,N-dimethyl-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-35-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-36-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 3-chloro-N-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-37-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N-methyl-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-39-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-cyclopropyl-3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-40-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-cyclobutyl-3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-41-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-44-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 578728-46-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5'-chloro-3-fluoro-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-48-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5'-methyl-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-51-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,5'-difluoro-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-53-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-(3',5'-difluoro-2'-methoxy[1,1'-biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C$$
 NH
 O
 Me
 O
 Me
 O

578728-55-9 HCAPLUS RN

 $\label{eq:cyclopropanetarboxamide} \text{Cyclopropanetarboxamide, N-[(1R)-1-[3,5'-difluoro-2'-(2-methyl-2H-tetrazol-1)]}$ CN 5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

578728-56-0 HCAPLUS

RN [1,1'-Biphenyl]-2-carboxylic acid, 5-chloro-3'-fluoro-4'-[(1R)-1-[[[1-CN [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$O$$

$$O$$

$$Me$$

RN 578728-57-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5-chloro-4'-[(lR)-1-[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ \hline F & & & \\ \hline C1 & & & \\ \hline O & & \\ \hline NH & & & \\ \hline O & & \\ \hline Me & & \\ \hline \end{array}$$

RN 578728-58-2 HCAPLUS
[1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-5-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578728-59-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-5-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & \\ & & & \\ \hline F & & & \\ \hline C1 & & & \\ \hline O & & \\ \hline NH & & \\ O & & \\ \hline Me & & \\ \hline \end{array}$$

RN 578728-60-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,5'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-61-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5'-chloro-3-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 578728-62-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[5'-chloro-3-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-63-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5'-methyl-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-64-0 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[3-fluoro-5'-methyl-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow NH \longrightarrow Me$$

$$O \longrightarrow Me$$

$$O \longrightarrow Me$$

RN 578728-66-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3',5difluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ \hline F & & & & \\ \hline \\ C1 & & & \\ \hline \\ O & & \\ \hline \\ NH & & \\ \hline \\ O & \\ \hline \\ Me & \\ \hline \\ O & \\ \hline \\ OMe \\ \hline \end{array}$$

RN 578728-68-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5'-chloro-3-fluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-70-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5'-methyl-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-71-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 3-chloro-3'-fluoro-N-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-72-0 HCAPLUS
CN Carbamic acid, [3-chloro-3'-fluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2yl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578728-73-1 HCAPLUS

CN Carbamic acid, [3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-75-3 HCAPLUS

CN Carbamic acid, [3,3'-difluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} O O$$

RN 578728-76-4 HCAPLUS

CN [1,1'-Biphenyl]-2-acetic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578728-77-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-78-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-chloro-3-fluoro-2'-(methoxymethyl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-79-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-(3',5'-dichloro-2'-hydroxy[1,1'-biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 NH
 O
 Me
 O
 O

RN 578728-84-4 HCAPLUS
[1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-6-methyl-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-86-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

RN 578728-87-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-3-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-88-8 HCAPLUS

CN

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-3-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ \hline F & & & \\ \hline C1 & & \\ \hline O & & \\ \hline NH & & \\ O & & \\ \hline Me & & \\ \hline O & \\ \hline OMe & \\ \hline \end{array}$$

IT 578729-02-9P 578729-03-0P 578729-04-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenylmethyl cycloalkanecarboxamides as bradykinin antagonists for treatment of conditions associated with bradykinin Bl pathway)

RN 578729-02-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578729-03-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-4-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow[O]{H} NH \xrightarrow[Me]{H} O \xrightarrow[Me]{O} OMe$$

RN 578729-04-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-4methyl-, methyl ester (9CI) (CA INDEX NAME)

IT 578729-07-4P 578729-11-0P 578729-19-8P

578729-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biphenylmethyl cycloalkanecarboxamides as bradykinin antagonists for treatment of conditions associated with bradykinin B1 pathway)

RN 578729-07-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]carbonyl]amino]ethyl]-3-fluoro-,

methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578729-11-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[1-[[[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]carbonyl]amino]-1-methylethyl]-3-fluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578729-19-8 HCAPLUS

CN Carbamic acid, [1-[[[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578729-24-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

7

ACCESSION NUMBER:

2003:633358 HCAPLUS

DOCUMENT NUMBER:

139:179892

TITLE:

Preparation of N-biphenylmethyl

cycloalkanecarboxamides as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain

and inflammation

INVENTOR(S):

Wood, Michael R.; Anthony, Neville J.; Bock, Mark G.;

Feng, Dong-mei; Kuduk, Scott D.; Su, Dai-shi

; Wai, Jenny Miu-chun

PATENT ASSIGNEE(S):

Merck & Co., Inc., USA

· PCT Int. Appl., 72 pp. CODEN: PIXXD2 SOURCE:

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 2003065789 WO 2003065789	A2 200308 A3 200408		20030204
W: AE, AG, AL, CO, CR, CU, GM, HR, HU, LT, LU, LV, PT, RO, RU,	AM, AT, AU, ACZ, DE, DK, ID, IL, IN, MA, MD, MG, ISC, SD, SE,	AZ, BA, BB, BG, BR, BY, BZ DM, DZ, EC, EE, ES, FI, GB IS, JP, KE, KG, KR, KZ, LC MK, MN, MW, MX, MZ, NO, NZ SG, SK, SL, TJ, TM, TN, TR	, GD, GE, GH, , LK, LR, LS, , OM, PH, PL,
RW: GH, GM, KE, KG, KZ, MD, FI, FR, GB,	RU, TJ, TM, AGR, HU, IE,	SD, SL, SZ, TZ, UG, ZM, ZW AT, BE, BG, CH, CY, CZ, DE IT, LU, MC, NL, PT, SE, SI GN, GQ, GW, ML, MR, NE, SN 814 CA 2003-2473778	, DK, EE, ES, , SK, TR, BF,
EP 1476419 EP 1476419	A2 20041 B1 20060	201	20030204
R: AT, BE, CH, IE, SI, LT, JP 2005516979 AT 316954 ES 2256727 US 2005085667 US 7091380 PRIORITY APPLN. INFO.: OTHER SOURCE(S): GI	DE, DK, ES, LV, FI, RO, T 20050 T 20060 T3 20060 A1 20050 B2 20060	215 AT 2003-713689 716 ES 2003-3713689 421 US 2004-503502 815 US 2002-355062P US 2002-410775P WO 2003-US5782	, SE, MC, PT, , HU, SK 20030204 20030204 20030204 20040803 P 20020208 P 20020912 W 20030204
R41 NR1 NR2		10 503502	
R71	R6 .	•	

AB Title compds. [I; R1, R2 = H, alkyl; R4, R41 = H, halo, (substituted)

ΙT

```
alkyl; R5 = alkynyl, (substituted) alkyl, cycloalkyl, alkenyl,
aryl(alkyl), heterocyclyl(alkyl), etc.; R6 = halo, cyano, NO2, cycloalkyl,
(substituted) alkyl, alkenyl, amino, acylamino, heterocyclyl, etc.; R61,
R62 = H, R6; R7, R71 = H, halo, cyano, NO2, OH, CO2H, alkyl, haloalkyl,
etc.; with provisos], were prepared for treatment of pain and inflammation
(no data). Thus, a mixture of THF, H2O, K2CO3, Me 2-iodobenzoate,
4-cyanophenylboronic acid, and bis(tri-o-tolylphosphine)palladium(II)
chloride was refluxed 3.5 h, cooled to ambient temperature, and stirred
overnight to give Me 4'-cyano-1,1'-biphenyl-2-carboxylate. The latter in
2 M NH3 in MeOH with a 50% aqueous slurry of Raney Ni was stirred under H2 for
9 h to give a residue which was dissolved in Et20/Et0Ac prior to
introduction of HCl to give Me 4'-(aminomethyl)-1,1'-biphenyl-2-
carboxylate hydrochloride. To the free base of the above in THF was added
1-[(tert-butoxycarbonyl)amino]cyclopropanecarboxylic acid, Et3N, HOBt.H2O,
and EDCI and the mixture was stirred overnight to provide Me
4'-[[[[1-[(tert-butoxycarbonyl)amino]cyclopropyl]carbonyl]amino]methyl]-
1,1'-biphenyl-2-carboxylate. The latter was treated with HCl in
CH2Cl2/MeOH to give the deprotected amine which was treated with HOBt.H2O,
3,3,3-trifluoropropionic acid, Et3N, and EDCI in DMF to give 78% Me
4'-[[[[1-[(3,3,3-trifluoropropanoyl)amino]cyclopropyl]carbonyl]amino]methy
1]-1,1'-biphenyl-2-carboxylate.
578766-13-9P 578766-14-0P 578766-15-1P
578766-16-2P 578766-17-3P 578766-18-4P
578766-20-8P 578766-21-9P 578766-25-3P
578766-27-5P 578766-29-7P 578766-30-0P
578766-34-4P 578766-36-6P 578766-37-7P
578766-38-8P 578766-42-4P 578766-48-0P
578766-50-4P 578766-51-5P 578766-52-6P
578766-53-7P 578766-54-8P 578766-55-9P
578766-56-0P 578766-57-1P 578766-59-3P
578766-67-3P 578766-69-5P 578766-82-2P
578766-86-6P 578766-87-7P 578766-88-8P
578767-07-4P 578767-09-6P 578767-12-1P
578767-13-2P 578767-15-4P 578767-17-6P
578767-21-2P 578767-23-4P 578767-24-5P
578767-25-6P 578767-28-9P 578767-30-3P
578767-34-7P 578767-38-1P 578767-40-5P
578767-48-3P 578767-50-7P 578767-52-9P
578767-54-1P 578767-55-2P 578767-56-3P
578767-57-4P 578767-64-3P 578767-65-4P
578767-66-5P 578767-67-6P 578767-68-7P
578767-69-8P 578767-71-2P 578767-72-3P
578767-73-4P 578767-74-5P 578767-75-6P
578767-76-7P 578767-79-0P 578767-80-3P
578767-81-4P 578767-82-5P 578767-84-7P
578767-85-8P 578767-87-0P 578767-88-1P
578767-89-2P 578767-91-6P 578767-98-3P
578767-99-4P 578768-00-0P 578768-07-7P
578768-09-9P 578768-11-3P 578768-12-4P
578768-13-5P 578768-14-6P 578768-15-7P
578768-16-8P 578768-17-9P 578768-18-0P
578768-21-5P 578768-23-7P 578768-24-8P
578768-29-3P 578768-30-6P 578768-31-7P
578768-32-8P 578768-33-9P 578768-34-0P
578768-36-2P 578768-39-5P 578768-41-9P
578768-42-0P 578768-43-1P 578768-44-2P
578768-45-3P 578768-46-4P 578768-47-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
```

(Uses)
 (preparation of N-biphenylmethyl cycloalkanecarboxamides as bradykinin B1
 antagonists or inverse agonists useful in the treatment of pain and
 inflammation)

RN 578766-13-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3,3,3-trifluoro-1oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

RN 578766-14-0 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[methyl(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-15-1 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2S)-2-[(acetyloxy)methyl]-1[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-,

methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Updated Search

RN 578766-16-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2R)-2-(hydroxymethyl)-1[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-,
methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 578766-17-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[1[(methoxyoxoacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578766-18-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(aminooxoacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-20-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(cyanoacetyl)amino]cyclopropy

l]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-21-9 HCAPLUS

RN 578766-25-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2-methyl-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-27-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(methoxyacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-29-7 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2-thienylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578766-30-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(3,4dimethoxyphenyl)acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl
ester (9CI) (CA INDEX NAME)

RN 578766-36-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(phenylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-48-0 HCAPLUS [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(phenylthio)acetyl]amino]cyc

lopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-50-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(phenoxyacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-51-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3,3-dimethyl-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-52-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3-cyclopentyl-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-53-7 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3-methoxy-1,3-dioxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-54-8 HCAPLUS
[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & &$$

RN 578766-57-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(ethoxyacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-59-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3-nitro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-67-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(1H-pyrazol-1-ylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-69-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(1H-1,2,4-triazol-1-ylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)

 $\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$

(CA INDEX NAME)

RN 578766-82-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(1H-imidazol-1-ylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} N \\ \hline \\ N \\ \hline \\ CH_2 \\ \hline \\ C \\ \hline \\ O \\ \end{array}$$

$$\begin{array}{c} CH_2 \\ \hline \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ MeO-C \\ \hline \\ O \\ \end{array}$$

RN 578766-87-7 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(5-methyl-1H-1,2,4-triazol-3-yl)acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)

(CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & &$$

RN 578766-88-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[1-oxo-3-(1H-1,2,4-triazol-1-yl)propyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 578767-07-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2,2-dimethyl-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-09-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(trifluoroacetyl)amino]cyclop ropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-12-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-13-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(cyanoacetyl)amino]cyclopropy l]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-15-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-17-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-fluoro-2'-[(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-21-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-23-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,6-difluoro-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-24-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-6-methyl-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} \\ \hline \\ & \text{C-NH-CH}_2 \\ \hline & \text{NH-C-CH}_2\text{-CF}_3 \\ \hline \\ & \text{O} \\ \end{array}$$

RN 578767-25-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-6-methyl-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & & & \\ \hline \\ C-NH-CH_2 & & & \\ NH-C-CH_2-CF_3 & & & \\ \hline \\ O & & & \\ \end{array}$$

578767-28-9 HCAPLUS · RN

[1,1'-Biphenyl]-2-carboxylic acid, 3'-chloro-3-fluoro-4'-[[[[1-[(3,3,3-1)]]]-2-carboxylic acid, 3'-chloro-3-fluoro-4'-[[[[1-[(3,3,3-1)]]]]-2-carboxylic acid, 3'-chloro-3-fluoro-3CN trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

578767-30-3 HCAPLUS

RN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[[[[1-[(3,3,3-trifluoro-1-CN oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

578767-34-7 HCAPLUS RN

Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-CN y1)[1,1'-biphenyl]-4-y1]methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

$$F_{3}C-CH_{2}-C-NH$$

$$C-NH-CH_{2}$$

$$F$$

RN 578767-38-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

$$F_3C-CH_2-C-NH \\ C-NH-CH_2 \\ F$$

RN 578767-40-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(3,3'-difluoro-2'-methoxy[1,1'-biphenyl]-4-yl)methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-48-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-50-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(dichloroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-52-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(1-oxo-2-propenyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-54-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[[(2E)-1-oxo-2-butenyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 578767-55-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(1oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

RN 578767-56-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(difluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-57-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-(acetylamino)cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-65-4 HCAPLUS
CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-66-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(2,2-dichloro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-67-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$C-NH-CH_{2}$$

$$F$$

RN 578767-68-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(3,3'-difluoro-2'-methoxy[1,1'-biphenyl]-4-yl)methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-69-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(dichloroacetyl)amino]-N-[[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

RN 578767-71-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH \qquad N-O \\ C-NH-CH_{2} \\ O \qquad F$$

RN 578767-72-3 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(2,2-dichloro-1-oxopropyl)amino]-N-[[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI) (CA INDEX NAME)

RN 578767-73-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3-carboxy-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, 2-methyl ester (9CI) (CA INDEX NAME)

RN 578767-74-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(chlorodifluoroacetyl)amino]c yclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-75-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]cyclopropyl]carbonyl]amino]meth yl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-76-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(aminoacetyl)amino]cyclopropy
l]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX
NAME)

RN 578767-79-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(acetylamino)acetyl]amino]cy clopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-80-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1[(hydroxyacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578767-81-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[1,3-dioxo-3-(3-pyridinyl)propyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-82-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-84-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(bromoacetyl)amino]cyclopropy l]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-85-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3',6-difluoro-4'-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & F \\
 & C - NH - CH_2 \\
 & NH - C - CF_3 \\
 & O \\
\end{array}$$

RN 578767-87-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-88-1 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[[(2R)-2-amino-1-oxopropyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ H_2N & & & \\ Me & R & & \\ \hline \\ NH & O & \\ \end{array}$$

RN 578767-89-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(2R)-2-(acetylamino)-1-oxopropyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 578767-91-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-3-methyl-4'-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578767-98-3 HCAPLUS
CN Carbamic acid, [3,3'-difluoro-4'-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-99-4 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(2,2-difluoro-4-hydroxy-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-00-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(dimethylamino)acetyl]amino] cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-07-7 HCAPLUS

CN Carbamic acid, [[3,3'-difluoro-4'-[[[[1-[(trifluoroacetyl)-amino]cyclopropy 1]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-09-9 HCAPLUS

CN Carbamic acid, [[[3,3'-difluoro-4'-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-11-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(1,3-dioxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-12-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(3-methoxy-1,3-dioxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-13-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-14-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-dichloro-N-methyl-4'-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA
INDEX NAME)

RN 578768-15-7 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(2-hydroxy-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)

(CA INDEX NAME)

RN 578768-16-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N-methyl-4'-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 578768-17-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(3-hydroxy-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-18-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(3-hydroxy-2-methylene-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-21-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N,N-dimethyl-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 578768-23-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N-methyl-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 578768-24-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N-methoxy-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 578768-29-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2S)-2-(hydroxymethyl)-1[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-,
methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 578768-30-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2S)-2-(chloromethyl)-1[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-,
methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 578768-31-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[2-methylene-1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-32-8 HCAPLUS

Relative stereochemistry.

RN 578768-33-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2S)-2-[(methylthio)methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 578768-34-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2R)-2[(dimethylamino)methyl]-1-[(3,3,3-trifluoro-1oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester, rel-

Relative stereochemistry.

(9CI) (CA INDEX NAME)

RN 578768-39-5 HCAPLUS
CN Cyclopropanecarboxamide, N-[[3,5'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH-CH_{2}$$

$$N=0$$

$$N=0$$

$$F$$

RN 578768-41-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3',5-difluoro-4'-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578768-42-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[1[[(methylamino)oxoacetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-43-1 HCAPLUS
[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(dimethylamino)oxoacetyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI)
(CA INDEX NAME)

RN 578768-44-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[[2(dimethylamino)ethyl]amino]oxoacetyl]amino]cyclopropyl]carbonyl]amino]meth
yl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 578768-45-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[[[2-(methylsulfonyl)ethyl]amino]oxoacetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-47-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[[oxo[(2-phenylethyl)amino]acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$CO_{2}H$$

$$F_{3}C$$

dimethylethoxy)carbonyl]amino]cyclopropyl]carbonyl]amino]ethyl]-3-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 578727-64-7P 578727-65-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of N-biphenylmethyl cycloalkanecarboxamides as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation)

RN 578727-64-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-65-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N-methoxy-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

=> d his

```
(FILE 'HOME' ENTERED AT 19:10:40 ON 14 MAR 2007)
     FILE 'REGISTRY' ENTERED AT 19:10:46 ON 14 MAR 2007
               STRUCTURE UPLOADED
L1
             15 S L1
L2
            347 S L1 FULL
L3
     FILE 'HCAPLUS' ENTERED AT 19:16:20 ON 14 MAR 2007
              7 S L3
L4
              0 S L4 AND NEVILLE, A?/AU
L5
              1 S L4 AND GOMEZ, R?/AU
L6
              6 S L4 NOT L6
L7
              0 S L7 AND JOLLY, S?/AU
^{18}
              0 S L7 AND LIM, J?/AU
L9
              2 S L7 AND SU, D?/AU
L10
=> s 17 not 110
L11
             4 L7 NOT L10
=> s lll and anthony, n?/au
           135 ANTHONY, N?/AU
             0 L11 AND ANTHONY, N?/AU
L12
=> d lll, ibib abs hitstr, 1-4
L11 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
                         2006:1343127 HCAPLUS
ACCESSION NUMBER:
                         146:220125
DOCUMENT NUMBER:
                         Development of Orally Bioavailable and CNS Penetrant
TITLE:
                         Biphenylaminocyclopropane Carboxamide Bradykinin Bl
                         Receptor Antagonists
                         Kuduk, Scott D.; Di Marco, Christina N.; Chang, Ronald
AUTHOR(S):
                         K.; Wood, Michael R.; Schirripa, Kathy M.; Kim, June
                         J.; Wai, Jenny M. C.; DiPardo, Robert M.; Murphy,
                         Kathy L.; Ransom, Richard W.; Harrell, C. Meacham;
                         Reiss, Duane R.; Holahan, Marie A.; Cook, Jacquelynn;
                         Hess, J. Fred; Sain, Nova; Urban, Mark O.; Tang,
                         Cuyue; Prueksaritanont, Thomayant; Pettibone, Douglas
                         J.; Bock, Mark G.
                         Departments of Medicinal Chemistry, Neuroscience Drug
CORPORATE SOURCE:
                         Discovery, Pain Research, and Drug Metabolism, Merck
                         Research Laboratories, West Point, PA, 19486, USA
                         Journal of Medicinal Chemistry (2007), 50(2), 272-282
SOURCE:
                         CODEN: JMCMAR; ISSN: 0022-2623
                         American Chemical Society
PUBLISHER:
                         Journal
DOCUMENT TYPE:
                         English
LANGUAGE:
     A series of biphenylaminocyclopropane carboxamide based bradykinin B1
     receptor antagonists has been developed that possesses good
     pharmacokinetic properties and is CNS penetrant. Discovery that the
     replacement of the trifluoropropionamide in the lead structure with
     polyhaloacetamides, particularly a trifluoroacetamide, significantly
     reduced P-glycoprotein mediated efflux for the series proved essential.
     One of these novel bradykinin Bl antagonists (13b) also exhibited suitable
     pharmacokinetic properties and efficient ex vivo receptor occupancy for
```

further development as a novel approach for the treatment of pain and inflammation. 578727-67-0P 578727-68-1P 578727-69-2P ΤT 578727-81-8P 578727-90-9P 925215-11-8P 925215-12-9P 925215-13-0P 925215-14-1P 925215-15-2P 925215-16-3P RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of oral CNS penetrant biphenylaminocyclopropane carboxamide derivs. as bradykinin B1 receptor antagonists for treatment of pain and inflammation) 578727-67-0 HCAPLUS RN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-CN oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-

Absolute stereochemistry.

(CA INDEX NAME)

RN 578727-68-1 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-69-2 HCAPLUS Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-

Updated Search

5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-81-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-90-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 925215-11-8 HCAPLUS

(1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(2,2,2-trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 925215-12-9 HCAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 925215-13-0 HCAPLUS CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-chloro-3-fluoro-2'-(2-methyl-2H-

Updated Search

tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]-(CA INDEX NAME)

Absolute stereochemistry.

RN 925215-14-1 HCAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 925215-15-2 HCAPLUS CN INDEX NAME NOT YET ASSIGNED

$$F_{3}C \xrightarrow{NH} {0} {Me} CF_{3}$$

RN 925215-16-3 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-chloro-3-fluoro-2'-(1-oxopropyl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]-(CA INDEX NAME)

Absolute stereochemistry.

IT 578727-78-3
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of oral CNS penetrant biphenylaminocyclopropane carboxamide derivs. as bradykinin B1 receptor antagonists for treatment of pain and inflammation)

INTIAMMATION)

RN 578727-78-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & &$$

```
578727-87-4P 578727-92-1P 578727-95-4P
IT
     578727-96-5P 578767-48-3P 578767-50-7P
     578767-56-3P 578767-57-4P 578767-66-5P
     578767-74-5P 578768-13-5P 925214-98-8P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of oral CNS penetrant biphenylaminocyclopropane carboxamide
        derivs. as bradykinin B1 receptor antagonists for treatment of pain and
        inflammation)
     578727-87-4 HCAPLUS
RN
     [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-
CN
     (acetylamino)cyclopropyl]carbonyl]amino]ethyl]-3,3'-difluoro-, methyl
     ester (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

RN 578727-95-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(difluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-96-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578767-48-3 HCAPLUS

Updated Search

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578767-50-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(dichloroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-56-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(difluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-57-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-(acetylamino)cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-66-5 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2,2-dichloro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-74-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(chlorodifluoroacetyl)amino]c yclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-13-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 925214-98-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4!-[[[[1-[(2-chloro-2-fluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-,
methyl ester (CA INDEX NAME)

RN 578767-12-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'~[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

IT 925215-17-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oral CNS penetrant biphenylaminocyclopropane carboxamide derivs. as bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 925215-17-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-4'-[(1R)-1-[[[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

28

ACCESSION NUMBER: 20

2006:83153 HCAPLUS

DOCUMENT NUMBER:

144:304953

TITLE:

Cyclopropylamino Acid Amide as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B1 Receptor Antagonists Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Wan, Bang-Lin: Murphy, Kathy L.; Ransom, Richard W.;

AUTHOR(S):

Wan, Bang-Lin; Murphy, Kathy L.; Ransom, Richard W.; Chang, Raymond S. L.; Tang, Cuyue; Prueksaritanont, Thomayant; Detwiler, Theodore J.; Hettrick, Lisa A.;

SOURCE:

CN

Landis, Elizabeth R.; Leonard, Yvonne M.; Krueger, Julie A.; Lewis, Sidney D.; Pettibone, Douglas J.;

Freidinger, Roger M.; Bock, Mark G.

CORPORATE SOURCE:

Departments of Medicinal Chemistry, Neuroscience, Drug

Metabolism, and Chemical Biology, Merck Research

Laboratories, West Point, PA, 19486, USA

Journal of Medicinal Chemistry (2006), 49(4),

1231-1234

CODEN: JMCMAR; ISSN: 0022-2623

American Chemical Society PUBLISHER:

Journal DOCUMENT TYPE: English LANGUAGE:

CASREACT 144:304953 OTHER SOURCE(S):

Antagonism of the bradykinin Bl receptor represents a potential treatment for chronic pain and inflammation. Novel antagonists were designed that display low-nanomolar affinity for the human bradykinin B1 receptor and good bioavailability in the rat.


578766-13-9P TΤ

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cyclopropylamino acid amide as pharmacophore for diaminopyridine: bradykinin receptor antagonists preparation for potential treatment of chronic pain and inflammation)

578766-13-9 HCAPLUS RN

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3,3,3-trifluoro-1oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 31 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

HCAPLUS COPYRIGHT 2007 ACS on STN L11 ANSWER 3 OF 4

2005:1004708 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 143:306182

TITLE: Preparation of 1-aminocyclopropane-1-carboxamide

derivatives as bradykinin B1 antagonists Bock, Mark G.; Feng, Dong-Mei; Kuduk, Scott

PATENT ASSIGNEE(S): Merck & Co., Inc., USA .PCT Int. Appl., 40 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

INVENTOR(S):

PATENT	NO.	KI	ND I	DATE			ION NO		DATE	`_	
WO 2005085198 WO 2005085198					WO				20050225		
W:	AE, AG, CN, CO, GE, GH, LK, LR, NO, NZ, SY, TJ, BW, GH, AZ, BY, EE, ES,	AL, AM CR, CU GM, HR LS, LT OM, PG TM, TN GM, KE KG, KZ FI, FR	, AT, , CZ, , HU, , LU, , PH, , TR, , LS, , MD, , GB,	AU, AZ, DE, DK, ID, IL, LV, MA, PL, PT, TT, TZ,	BA, BB DM, DZ IN, IS MD, MG RO, RU UA, UG NA, SD TM, AT IE, IS	, EC, , JP, , MK, , SC, , US, , SL, , BE, , IT,	EE, E KE, H MN, M SD, S UZ, N SZ, T BG, C LT, I	EG, ES, KG, KP, MW, MX, SE, SG, VC, VN, TZ, UG, CH, CY, LU, MC,	FI, GB, KR, KZ, MZ, NA, SK, SL, YU, ZA, ZM, ZW, CZ, DE, NL, PL,	GD, LC, NI, SM, ZM, AM, DK, PT,	ZW
CA 255 EP 172 R:	MR, NE, 5219836 7858 3143 AT, BE, IS, IT,	SN, TD A A BG, CH LI, LT	, TG 1 1 2 , CY,	20050915 20050915 20061122 CZ, DE, MC, NL,	AU CA EP DK, EE	2005- 2005- 2005- , ES,	219836 255785 714101 FI, I	6 58 1 FR, GB, SI, SK,	20050 20050 20050 GR, HU, TR, LV)225)225)225 IE,	
PRIORITY AP OTHER SOURCE		• :			US WO	2004-	549379	9 P	20030 P 20040 W 20050	302	

AB Title compds. I [wherein Rla, Rlb, Rlc = H or F; R2 = H or Cl; R3 = Cl or

F; R4 = (un)substituted (cyclo)alkyl, aryl or heterocycle, or pharmaceutically acceptable salts thereof) were prepared as antagonists or inverse agonists of bradykinin receptors, especially as antagonists of bradykinin receptor B1. For instance, II was synthesized by acylation of dihydrochloride salt of the corresponding cyclopropanamine with 5-methylisoxazole-3-carbonyl chloride in the presence of DIPEA. I exhibited affinity for the B1 receptor with IC50 values of $<5\,\mu\text{M}$. Therefore, I and their pharmaceutical compns. (examples given) are useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

associated with the Bradykinin Bi pathwa 864641-51-0P 864641-56-5P 864641-76-9P 864641-88-3P 864641-94-1P 864642-05-7P 864642-20-6P 864642-32-0P 864642-35-3P 864642-37-5P 864642-60-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminocyclopropanecarboxamide derivs. as bradykinin Bl antagonists)

RN 864641-51-0 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864641-56-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

RN 864641-76-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3-chloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864641-88-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864641-94-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1[[(methylsulfonyl)acetyl]amino]- (9CI) (CA INDEX NAME)

RN 864642-05-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3-chloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864642-20-6 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864642-32-0 HCAPLUS .

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (9CI) (CA INDEX

Updated Search

NAME)

Absolute stereochemistry.

RN 864642-35-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(1-oxobutyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864642-37-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2-methyl-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 864642-60-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(difluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 864642-89-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminocyclopropanecarboxamide derivs. as bradykinin Bl antagonists)

RN 864642-89-7 HCAPLUS

CN Carbamic acid, [1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:203618 HCAPLUS

DOCUMENT NUMBER:

140:253570

TITLE:

Preparation of N-biarylmethylaminocycloalkanecarboxami

de as bradykinin B1 antagonists

INVENTOR(S):

Kuduk, Scott D.; Wood, Michael R.; Bock, Mark G.

PATENT ASSIGNEE(S):

Merck & Co., Inc., USA PCT Int. Appl., 59 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE		
WO 2004019868 WO 2004019868		WO 2003-US26628	20030825		
		BA, BB, BG, BR, BY,			
		DZ, EC, EE, ES, FI,			
		JP, KE, KG, KR, KZ,			
		MN, MW, MX, MZ, NI,			
PH, PL, PT,	RO, RU, SC, SD,	SE, SG, SK, SL, SY,	TJ, TM, TN, TR,		
		VN, YU, ZA, ZM, ZW			
		SL, SZ, TZ, UG, ZM,			
		BE, BG, CH, CY, CZ,			
		LU, MC, NL, PT, RO,			
BF, BJ, CF,	CG, CI, CM, GA,	GN, GQ, GW, ML, MR,	NE, SN, TD, TG		
		CA 2003-2495914			
		AU 2003-265674			
		BR 2003-13239			
		EP 2003-791763			
		GB, GR, IT, LI, LU,			
IE, SI, LT,	LV, FI, RO, MK,	CY, AL, TR, BG, CZ,	EE, HU, SK		
CN 1678320	A 20051005	CN 2003-820293	20030825		
JP 2005537323	T 20051208	JP 2004-532994	20030825		
		US 2005-523911	20050208		
US 7163951	B2 20070116				
NO 2005001539	A 20050525				
PRIORITY APPLN. INFO.:		US 2002-406742P			
		WO 2003-US26628	W 20030825		
OTHER SOURCE(S):	MARPAT 140:2535	70	•		

GΙ

```
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
     Title compds. I [Het = pyridyl, pyrimidinyl, N-oxide thereof; R1-2 = H,
AB
     alkyl; R3a-3b = H, alkyl; R4a-4b = H, halo, alkyl, etc.; R5 = alkyl,
     cycloalkyl, alkynyl, alkenyl, etc.; R6a = alkyl, cycloalkyl, alkenyl,
     etc.; R6b-6c = H and not more than one of R6a-6c = heterocycle; R7a-7b =
     H, halo, CN, etc.; m = 0-3] are prepared For instance, 1-[((pyrimidin-5-
     yl)carbonyl)amino]cyclobutanecarboxylic acid (preparation given) is coupled to
     Me 2-[2-(aminomethyl)pyrimidin-5-yl]-6-fluorobenzoate (preparation given; DMF,
     HOBt, EDCI, Et3N) to give II. Compds. of the invention have affinity for the bradykinin Bl receptor at less than 5 \mu M . I are useful for the
     treatment of pain and inflammation.
     669066-20-0P, N-[[3-Chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-
ΙT
     yl)phenyl]pyridin-2-yl]methyl}-1-[(trifluoroacetyl)amino]cyclopropanecarbo
     xamide 669066-34-6P, Methyl 2-fluoro-6-[5-fluoro-6-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]pyridin-3-
     yl]benzoate 669066-47-1P, 1-[[(2,2,2-
     Trifluoroethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-(fluoro)phenyl]-
     3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-48-2P, 1-[[(Dichloromethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-49-3P,
     1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-
     (fluoro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-50-6P, 1-[[(1,1-Dichloroethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy) -3-(fluoro)phenyl]-3-chloropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-51-7P
     669066-52-8P 669066-53-9P, 1-
     (chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-54-0P, 1-[[(Difluoromethyl)carbonyl]amino]-1-[[[[5-[2-1]]]]
     (carbomethoxy) -3-(chloro) phenyl] -3-chloropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-55-1P
     669066-56-2P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy)-3-(chloro)phenyl]-3-fluoropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-57-3P,
     1-[[(Dichlorofluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-
     (chloro)phenyl]-3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-58-4P, 1-[[(Difluoromethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy)-3-(chloro)phenyl]-3-fluoropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-59-5P,
     1-[[[(Carbomethoxy)amino]carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-
     (chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-60-8P, 1-[[[(Carbomethoxy)amino]carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy)-3-(chloro)phenyl]pyridin-2-yl]methyl]amino]carbonyl]cyclopr
     opane 669066-61-9P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-
     [2-(carbomethoxy)-5-(chloro)phenyl]-3-chloropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-62-0P,
     1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-(chloro)-]]]]
     5-(chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-63-1P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-64-2P,
     1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-(fluoro)-fluoro]]]]]
```

```
5-(chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
669066-65-3P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-1]]]]
(carbomethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-67-5P
669066-68-6P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-
methyl-2H-tetrazol-5-yl)-3-(fluoro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-69-7P
669066-70-0P, 1-[[(Difluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-
methyl-2H-tetrazol-5-yl)-3-(fluoro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-71-1P,
1-[[(Chlorodifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-methyl-2H-tetrazol-
5-y1)-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopr
opane 669066-72-2P 669066-73-3P 669066-74-4P
, 1-[[(Methyl)carbonyl]amino]-1-[[[[5-[2-(2-methyl-2H-tetrazol-5-yl)-3-
 (chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
 669066-75-5P 669066-76-6P 669066-77-7P,
1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-m
y1)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-78-8P
 669066-79-9P 669066-80-2P, 1-
 [[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-methyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)]-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-5-yl)-Hethyl-2H-tetrazol-
 3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
 yl]methyl]amino]carbonyl]cyclopropane 669066-81-3P,
 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(5-methyl-1,2,4-oxadiazol-1]]]]]]
 3-y1)-5-(chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopr
 opane 669066-82-4P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-
 [2-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(chloro)-5-(chloro)phenyl]-3-
 chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane 669066-83-5P
  , 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(5-methyl-1,2,4-
 oxadiazol-3-yl)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
 yl]methyl]amino]carbonyl]cyclopropane 669066-85-7P,
 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-[2-fluoro-2-in]]amino]-1-[[instruction]]amino]]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]-1-[instruction]amino]amino]-1-[instruction]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino]amino
  (fluoromethyl)ethoxy]-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-
 yl]methyl]amino]carbonyl]cyclopropane 669066-86-8P,
  1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-[2-fluoro-2-
  (fluoromethyl)ethoxy]-3-(chloro)-5-(chloro)phenyl]-3-pyridin-2-
  yl]methyl]amino]carbonyl]cyclopropane 669066-87-9P,
  1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-[(carbomethoxy)oxy]-3-
  (fluoro)phenyl]-3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
  669066-88-0P 669066-99-3P 669067-00-9P
  669067-01-0P, (R) -1-[[(Trifluoromethyl) carbonyl] amino] <math>-1-[[[1-[5-1]]]
  [2-(carbomethoxy)-3-(chloro)phenyl]-3-chloropyridin-2-
  yl]ethyl]amino]carbonyl]cyclopropane 669067-02-1P,
  (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-methyl-1,2,4-[3-met
  oxadiazol-5-yl)-3-(fluoro)phenyl]-3-chloropyridin-2-
  yl]ethyl]amino]carbonyl]cyclopropane 669067-03-2P,
   (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (trifluoromethyl) - 3 - [1 - [2 - (trifluoromethyl) - 3 - (trifluoromethyl) - 3 - [2 - (trifluoromethyl) - 3 - (trifluoromethyl) -
   (fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
  669067-04-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-1]]669067-04-3P]669067-04-3P]669067-04-3P
  [2-(trifluoromethyl)-3-(fluoro)phenyl]pyridin-2-
  yl]ethyl]amino]carbonyl]cyclopropane 669067-05-4P,
   (chloro)phenyl]pyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
  669067-06-5P, (R) -1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-1]]669067-06-5P]]
   [2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-3-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-3-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(5-methyl-3-yl)-3-(5-methyl-3-yl)-3-(5-methyl-3-yl)-3-(5-methyl-3-y
  yl]ethyl]amino]carbonyl]cyclopropane 669067-07-6P,
   (fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
   669067-08-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-^{\circ}]
```

```
[2-(carbomethoxy)-3-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-09-8P,
(R)-1-[[(Difluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(carbomethoxy)-3-[]]]]]
(chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-10-1P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
[2-(trifluoromethyl)-3-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-11-2P,
(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-12-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-^{\circ}
[2-(trifluoromethyl)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-13-4P,
(R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(5-methyl-1,2,4-1])]]]]
oxadiazol-3-yl)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-15-6P,
trifluoroethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-16-7P,
(chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-17-8P 669067-18-9P 669067-19-0P,
3-(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-20-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
[2-(2-methyl-2H-tetrazol-5-yl)-3-(chloro)-5-(chloro)phenyl]-3-
fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-21-4P
    (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(2-methyl-2H-1]]]]]]
tetrazol-5-yl)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-22-5P,
(chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-23-6P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
[2-(2-methyl-2H-tetrazol-5-yl)-3-(fluoro)-5-(chloro)phenyl]-3-
fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-24-7P
, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(carbomethoxy)-3-
(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclo
propane 669067-25-8P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-
[[[1-[5-[2-(2-fluoroethoxycarbonyl)-3-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-26-9P
669067-27-0P, (R)-1-[[(Difluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-1]]669067-27-0P]669067-27-0P]669067-27-0P
(carbomethoxy) -3-(chloro) -5-(chloro) phenyl] -3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-28-1P,
(R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(carboethoxy)-3-[]]]]
(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclo
propane 669067-29-2P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-
[[[1-[5-[2-(carboethoxy)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-30-5P,
fluoroethoxycarbonyl)-3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-31-6P,
 (R) -1 - [\ [\ (Trifluoromethyl)\ carbonyl\ ]\ amino\ ] -1 - [\ [\ [1-[5-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbom
 (fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclo
propane 669067-32-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-
[[[1-[5-[2-(2-fluoroethoxycarbonyl)-3-(fluoro)-5-(chloro)phenyl]-3-
chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-33-8P
 , (R)-1-[[(Methyl)carbonyl]amino]-1-[[[1-[5-[2-(2-methyl-2H-tetrazol-5-yl)-
3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-34-9P,
 (R) - 1 - [[(Trifluoromethyl) carbonyl] amino] - 1 - [[[1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - (carboethoxy) - 3 - [[(1 - [5 - [2 - [(1 - [5 - [2 - [carboethoxy) - 3 - [[(1 - [5 - [carboethoxy) - 3 - [[(1 - [carboethoxy) - [[(1 - [carboethoxy) - 3 - [[(1 - [carboethoxy) - 3 - [[(1 - [carboethoxy) - [(1 - [carboethoxy) - [[(1 - [carboethoxy) - [(1 - [carboethoxy) - [(1 - [carboethox) - [(1 - [carboethox) - [[(1 - [carboethox) - [(1 - [carboethox)
```

```
(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-35-0P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-^{\circ}]
[2-(carboethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-37-2P,
 (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (carboethoxy) - 3 - [2 - (carboethoxy) - 2 - (carboethoxy) - 3 - [2 - (carboethoxy) - 3 - [2 - (carboethoxy) - 3 - (carboethoxy) - 3 - [2 - (carboethoxy) - 3 - (carboethoxy) - 3 - [2 - (carboethoxy) - 3 - (carboethoxy) - 3 - (carboethoxy) - [2 - (carboethoxy) - 3 - (carboethoxy) - 3 - (carboethoxy) - (car
 (fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-38-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
[2-(cyano)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-39-4P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (ethoxy) - 3 - (fluoro) - (ethoxy) - 3 - (fluoro) - (ethoxy) - 3 - (ethoxy) - (ethox
5-(chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-40-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(2-fluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-42-9P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (ethoxy) - 3 - (fluoro) - (ethoxy) - 3 - (fluoro) - (ethoxy) - 3 - (ethoxy) - (e
5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-46-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-1]]669067-46-3P]]
 [2-(2,2,2-trifluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-51-0P,
 (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2 - (2, 2))))]]]]]]]]]]]]]]]]]]
difluoroethoxycarbonyl)-3-(fluoro)-5-(chloro)phenyl]pyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-53-2P,
 (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (2, 2 - difluoroethoxy) - (2, 2 - difluoroethoxy) - (2, 2 - difluoroethoxy) - (3, 2 - difluoroethoxy) - (3, 2 - difluoroethoxy) - (4, 2 - difluoroethoxy) - 
3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-54-3P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (ethoxy) - 3 - (chloro) - (ethoxy) - 3 - (ethoxy) - (e
 5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-58-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(ethoxy)-3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-59-8P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (2, 2 - difluoroethoxy) - (2, 2 - difluoroethoxy) - (2, 2 - difluoroethoxy) - (3, 2 - difluoroethoxy) - (3, 2 - difluoroethoxy) - (4, 2 - difluoroethoxy) -
3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-60-1P,
 (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (2, 2, 2 - (2, 2, 2)]]]]]] -1 - [[(1 - [5 - [2 - (2, 2, 2, 2)])]]]]
trifluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-64-5P,
 (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(ethoxy)-3-(chloro)-1-[[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethox
 5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-65-6P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
  [2-(2,2-difluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-
vl]ethyl]amino]carbonyl]cyclopropane 669067-68-9P,
 trifluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-69-0P
 669067-71-4P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
  [2-(2,2-difluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-72-5P,
  (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-[(cyclopropyl)oxy]-3-[(multiple form)carbonyl]amino]]-1-[[[1-[5-[2-[(cyclopropyl)oxy]-3-[(multiple form)carbonyl]amino]]-1-[[[1-[5-[2-[(cyclopropyl)oxy]-3-[(multiple form)carbonyl]amino]]-1-[[[1-[5-[2-[(cyclopropyl)oxy]-3-[(multiple form)carbonyl]amino]]-1-[[[1-[5-[2-[(cyclopropyl)oxy]-3-[(multiple form)carbonyl]amino]]-1-[[[1-[5-[2-[(cyclopropyl)oxy]-3-[(multiple form)carbonyl]amino]]-1-[[[1-[5-[2-[(cyclopropyl)oxy]-3-[(multiple form)carbonyl]amino]]-1-[[[1-[5-[2-[(cyclopropyl]oxy]-3-[(multiple form)carbonyl]amino]]-1-[[(multiple form)carbonyl]amino]]-1-[[(multiple form)carbonyl]amino]]-1-[[(multiple form)carbonyl]amino]]-1-[[(multiple form)carbonyl]amino]]-1-[[(multiple form)carbonyl]amino]]-1-[(multiple form)carbonyl]amino]-1-[(multiple form)carbonyl]amino]-1-[(multiple form)carbonyl]amino]-1-[(multiple form)carbonyl]
  (fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclo
propane 669067-74-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-
 [[[1-[5-[2-(cyano)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
  (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
                   (preparation of N-biarylmethylaminocycloalkanecarboxamide as bradykinin B1
                   antagonists)
  669066-20-0 HCAPLUS
 Cyclopropanecarboxamide, N-[[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-
```

RN

CN

5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME) .

RN 669066-34-6 HCAPLUS

CN Benzoic acid, 2-fluoro-6-[5-fluoro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-47-1 HCAPLUS

CN Benzoic acid, 2-fluoro-6-[5-fluoro-6-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-48-2 HCAPLUS

CN Benzoic acid, 2-[6-[[[[1-[(dichloroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-5-fluoro-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-49-3 HCAPLUS

CN Benzoic acid, 2-[5-chloro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carb onyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-50-6 HCAPLUS

CN Benzoic acid, 2-[5-chloro-6-[[[[1-[(2,2-dichloro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-51-7 HCAPLUS

INDEX NAME)

RN 669066-52-8 HCAPLUS

CN Benzoic acid, 2-[5-chloro-6-[[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & O \\
 & NH-C-CF_2-C1 \\
 & C=O \\
 & NH-CH_2 \\
 & N \\
 & C-OMe \\
 & O
\end{array}$$

RN 669066-53-9 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
\hline
C & NH - CH_2 \\
\hline
NH - C - CF_3 \\
\hline
C & C - OMe \\
\hline
C & C \\
\hline
C & C - OMe \\
\hline
C & C - OMe$$

RN 669066-54-0 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[[[[1-[(difluoroacetyl)amino]cyclopro

pyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & C1 \\ \hline \\ NH-C-CH_2 & N \\ \hline \\ O & C1 \\ \hline \\ C-OMe \\ \hline \\ O & C1 \\ \hline \\ C-OMe \\ \hline \\ O & C1 \\ \hline \\ C-OMe \\ \hline \\ O & C1 \\ \hline \\ C-OMe \\ \hline \\ O & C1 \\ \hline \\ C-OMe \\ \hline \\ O & C1 \\ \hline \\ C-OMe \\ \hline \\ O & C1 \\ \hline \\ O & OMe \\$$

RN 669066-55-1 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[[[[1-[(chlorodifluoroacetyl)amino]cy clopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-56-2 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & F \\ \hline C-NH-CH_2 & F \\ \hline NH-C-CF_3 & N \\ \hline O & C-OMe \\ \hline \end{array}$$

RN 669066-57-3 HCAPLUS

CN Benzoic acid, 2-chloro-6-[6-[[[[1-[(dichlorofluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-58-4 HCAPLUS
CN Benzoic acid, 2-chloro-6-[6-[[[[1-[(difluoroacetyl)amino]cyclopropyl]carbo
nyl]amino]methyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX

 $\begin{array}{c|c} O & F \\ \hline \\ C-NH-CH_2 & \hline \\ NH-C-CHF_2 & N \\ \hline \\ O & C-OMe \\ \hline \end{array}$

RN 669066-59-5 HCAPLUS
CN Benzoic acid, 2-chloro-6-[5-chloro-6-[[[[1-[[[(methoxycarbonyl)amino]carbonyl]amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-60-8 HCAPLUS
CN Benzoic acid, 2-chloro-6-[6-[[[[1-[[[(methoxycarbonyl)amino]carbonyl]amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA

INDEX NAME)

RN 669066-61-9 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 & C1 \\
C - NH - CH_2 & I \\
NH - C - CF_3 & C - OMe
\end{array}$$

RN 669066-62-0 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[5-chloro-6-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-,
methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C - NH - CH_2 & C1 \\
NH - C - CF_3 & N \\
O & MeO - C
\end{array}$$

RN 669066-63-1 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinýl]-,
methyl ester (9CI) (CA INDEX NAME)

RN 669066-64-2 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C - NH - CH_2 & C1 \\
NH - C - CF_3 & N \\
0 & MeO - C \\
0 & F
\end{array}$$

RN 669066-65-3 HCAPLUS

CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-,
methyl ester (9CI) (CA INDEX NAME)

RN 669066-67-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

RN 669066-68-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-fluoro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$O$$

$$N=N$$

$$N=N$$

$$F$$

RN 669066-69-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(difluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669066-70-0 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(difluoroacetyl)amino]-N-[[3-fluoro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

$$F_{2}CH-C-NH$$

$$Me$$

$$N$$

$$N$$

$$N$$

$$N$$

RN 669066-71-1 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[[3-fluoro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

Me N F
$$C-NH-CH_2$$
 $NH-C-CF_2-C1$ O

RN 669066-72-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C & NH - CH_2 \\
NH - C - CF_3 \\
0 & Me \\
N - N
\end{array}$$

RN 669066-73-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(difluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C & NH - CH_2 \\
NH - C - CHF_2 \\
O & Me \\
N - N
\end{array}$$

$$\begin{array}{c|c}
C1 \\
N - N
\end{array}$$

RN 669066-74-4 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

RN 669066-75-5 HCAPLUS

CN Carbamic acid, [[[1-[[[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]amino]carbonyl]cyclopropyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

$$MeO-C-NH-C-NH$$

$$MeO-NH-C-NH$$

$$Me$$

$$N=N$$

RN 669066-76-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[5-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$O$$

$$Me$$

$$N=N$$

$$C1$$

$$N$$

$$N=N$$

$$C1$$

RN 669066-77-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[[5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669066-78-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C & C1 \\
C & C1
\end{array}$$

$$\begin{array}{c|c}
C1 \\
N & C1
\end{array}$$

$$\begin{array}{c|c}
C1 \\
N & C1
\end{array}$$

$$\begin{array}{c|c}
N & C1
\end{array}$$

$$\begin{array}{c|c}
N & C1
\end{array}$$

RN 669066-79-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$O$$

$$N=N$$

$$N=N$$

$$F$$

$$C1$$

$$N=N$$

$$N=N$$

$$F$$

RN 669066-80-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$O$$

$$Me$$

$$N$$

$$N$$

$$N$$

$$F$$

$$C1$$

RN 669066-81-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[5-chloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669066-82-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C - NH - CH_2 & C1 \\
NH - C - CF_3 & N
\end{array}$$

$$\begin{array}{c|c}
C1 & C1 \\
N & C1
\end{array}$$

$$\begin{array}{c|c}
N & C1
\end{array}$$

RN 669066-83-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[[5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669066-85-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3,5-dichloro-2-(2,3-difluoropropoxy)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669066-86-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[[5-[3,5-dichloro-2-(2,3-difluoropropoxy)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669066-87-9 HCAPLUS

CN Carbonic acid, 2-fluoro-6-[5-fluoro-6-[[[[1-[(trifluoroacetyl)amino]cyclop ropyl]carbonyl]amino]methyl]-3-pyridinyl]phenyl methyl ester (9CI) (CA INDEX NAME)

RN 669066-88-0 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669066-99-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-1-[(difluoroacetyl)amino]- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.

RN 669067-00-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-01-0 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-,
methyl ester (9CI) (CA INDEX NAME)

RN 669067-02-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-03-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAMÉ)

$$F_3C$$
 NH
 O
 Me
 $C1$
 CF_3

RN 669067-04-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3-fluoro-2-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 NH
 O
 Me
 CF_3

RN 669067-05-4 HCAPLUS

CN Benzoic acid, 2-chloro-6-[6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-06-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669067-07-6 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} F$$

RN 669067-09-8 HCAPLUS

CN Benzoic acid, 2-chloro-6-[6-[(1R)-1-[[[1-[(difluoroacetyl)amino]cyclopropy l]carbonyl]amino]ethyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_2CH \qquad NH \qquad O \qquad Me \qquad F$$

RN 669067-10-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3-chloro-2-(trifluoromethyl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-11-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(difluoromethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} F$$

RN 669067-12-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-2-(trifluoromethyl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$F$$

$$CF_{3}$$

RN 669067-13-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 669067-15-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} F$$

RN 669067-16-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(2,5-dichlorophenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow \begin{matrix} H \\ N \\ N \end{matrix} \qquad \begin{matrix} R \\ Me \end{matrix} \qquad \begin{matrix} C_{1} \\ F \end{matrix}$$

RN 669067-17-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,3-difluoropropoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$F_3C$$
 NH
 O
 Me
 F
 CH_2F

RN 669067-18-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,3-difluoropropoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 O
 O
 Me
 O
 CH_2F

RN 669067-19-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,2-difluoroethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

NH

N

CHF2

RN 669067-20-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-

[(trifluoroacetyl)amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-21-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-22-5 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 669067-23-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-24-7 HCAPLUS

CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 669067-25-8 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-26-9 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[6-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino] cyclopropyl]carbonyl]amino]ethyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-27-0 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[6-[(1R)-1-[[[1-[(difluoroacetyl)amino]cyclop ropyl]carbonyl]amino]ethyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669067-28-1 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-6-fluoro-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$O$$

$$NH$$

$$O$$

$$Me$$

$$C1$$

$$O$$

$$OEt$$

RN 669067-29-2 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 669067-30-5 HCAPLUS

CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 NH
 O
 Me
 F
 O
 O
 CH_2F

RN 669067-31-6 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

$$F_{3}C \xrightarrow[O]{H} \xrightarrow[NH]{H} \xrightarrow[O]{H} \xrightarrow[NH]{R} \xrightarrow[O]{C1}$$

RN 669067-32-7 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-6fluoro-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 $C1$
 O
 $CH_{2}F$

RN 669067-33-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

669067-37-2 HCAPLUS RN

Benzoic acid, 2-fluoro-6-[5-fluoro-6-[(1R)-1-[[[1-CN [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN669067-38-3 HCAPLUS CN

Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-cyanophenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEXNAME)

$$F_3C$$
 NH
 O
 Me
 F
 $C1$
 CN
 $C1$

RN 669067-39-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(5-chloro-2-ethoxy-3-fluorophenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-40-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-fluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$O$$

$$Me$$

$$F$$

RN 669067-42-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(5-chloro-2-ethoxy-3-fluorophenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} C1$$

RN 669067-46-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow \begin{matrix} H \\ N \\ N \\ N \end{matrix} \qquad \begin{matrix} C1 \\ F \\ O \end{matrix} \qquad \begin{matrix} CF_{3} \\ CF_{3} \end{matrix}$$

RN 669067-51-0 HCAPLUS

CN Benzoic acid, 4-chloro-2-fluoro-6-[6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, 2,2-difluoroethyl ester (9CI) (CA INDEX NAME)

RN 669067-53-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-2-(2,2-difluoroethoxy)-5-fluorophenyl]-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$C1$$

$$O$$

$$CHF_{2}$$

RN 669067-54-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3-chloro-2-ethoxy-5-fluorophenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C$$
 NH
 O
 Me
 $C1$
 OEt

RN 669067-58-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(2-ethoxy-3,5-difluorophenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 $C1$
 OEt

RN 669067-59-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[2-(2,2-difluoroethoxy)-3,5-difluorophenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C$$
 NH
 O
 Me
 $C1$
 O
 CHF_{2}

RN 669067-60-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-5-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$O$$

$$NH$$

$$O$$

$$Me$$

$$C1$$

$$CF_{3}$$

RN 669067-64-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CAINDEX NAME)

RN 669067-65-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} C1$$

RN 669067-68-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669067-69-0 HCAPLUS

CN Benzoic acid, 4-chloro-2-[6-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino]cycl opropyl]carbonyl]amino]ethyl]-3-pyridinyl]-6-fluoro-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-71-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C$$

$$O$$

$$NH$$

$$O$$

$$Me$$

$$C1$$

$$C1$$

$$F$$

$$CHF_{2}$$

RN 669067-72-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[2-(cyclopropyloxy)-3,5-difluorophenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-74-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-cyanophenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$C1$$

$$CN$$

$$CN$$

$$C1$$

RN 669066-38-0 HCAPLUS
CN Benzoic acid, 2-[6-[[[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]
 carbonyl]amino]methyl]-5-fluoro-3-pyridinyl]-6-fluoro-, methyl ester (9CI)
 (CA INDEX NAME)

$$\begin{array}{c} O \\ | \\ NH-C-OBu-t \\ C \longrightarrow O \\ NH-CH_2 \longrightarrow \\ N \longrightarrow \\ C-OMe \\ | \\ O \end{array}$$

=> file caold SINCE FILE TOTAL COST IN U.S. DOLLARS ENTRY SESSION 49.89 225.80 FULL ESTIMATED COST DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -5.46 -5.46

FILE 'CAOLD' ENTERED AT 19:19:31 ON 14 MAR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.